Literature DB >> 19035982

Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.

V W-S Wong1, G L-H Wong, S W-C Tsang, A Y Hui, A W-H Chan, P C-L Choi, A M-L Chim, S Chu, F K-L Chan, J J-Y Sung, H L-Y Chan.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent countries. Serum alanine aminotransferase (ALT) level is commonly performed to monitor NAFLD patients, but its clinical relevance is unclear. AIM: To evaluate the metabolic and histological features of NAFLD patients with different ALT levels.
METHODS: A total of 173 consecutive patients with biopsy-proven NAFLD were studied. Patients with persistently normal ALT and those with abnormal ALT were compared.
RESULTS: Patients with persistently normal ALT had lower steatosis grade than patients with abnormal ALT, but they had similar degree of lobular inflammation, ballooning and fibrosis. Among 19 patients with ALT below 0.5 times the upper limit of normal (ULN) at the time of liver biopsies, 8 (42%) and 3 (16%) had steatohepatitis and significant fibrosis respectively. The within-patient coefficient of variance was similarly high in patients with simple steatosis and steatohepatitis (33.5). Age and glucose, but not ALT, were independent factors associated with significant fibrosis. DISCUSSION: Metabolic factors, but not ALT, are associated with histological severity. Patients with ALT < 0.5 x ULN may still have non-alcoholic steatohepatitis (NASH) and significant fibrosis. Evaluation of NAFLD patients should be based on metabolic risk factors, but not ALT level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19035982     DOI: 10.1111/j.1365-2036.2008.03896.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  32 in total

1.  A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients.

Authors:  Alex Ulitsky; Ashwin N Ananthakrishnan; Richard Komorowski; James Wallace; Sri Naveen Surapaneni; Jose Franco; Kia Saeian; Samer Gawrieh
Journal:  Obes Surg       Date:  2010-06       Impact factor: 4.129

2.  Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.

Authors:  Shahinul Alam; Utpal Das Gupta; Mahbubul Alam; Jahangir Kabir; Ziaur Rahman Chowdhury; A K M Khorshed Alam
Journal:  Indian J Gastroenterol       Date:  2014-07-15

3.  Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease.

Authors:  Grace Lai-Hung Wong; Henry Lik-Yuen Chan
Journal:  Hepatol Int       Date:  2015-03-11       Impact factor: 6.047

4.  Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease.

Authors:  Say-Yee Loo; Wah-Kheong Chan
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

5.  A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.

Authors:  Tomohiro Ogawa; Hideki Fujii; Katsutoshi Yoshizato; Norifumi Kawada
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

6.  Insecticide and metal exposures are associated with a surrogate biomarker for non-alcoholic fatty liver disease in the National Health and Nutrition Examination Survey 2003-2004.

Authors:  Banrida Wahlang; Savitri Appana; K Cameron Falkner; Craig J McClain; Guy Brock; Matthew C Cave
Journal:  Environ Sci Pollut Res Int       Date:  2019-12-23       Impact factor: 4.223

Review 7.  Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Authors:  Michelle T Long; Sanil Gandhi; Rohit Loomba
Journal:  Metabolism       Date:  2020-05-05       Impact factor: 8.694

8.  Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Authors:  J H Hoofnagle; M L Van Natta; D E Kleiner; J M Clark; K V Kowdley; R Loomba; B A Neuschwander-Tetri; A J Sanyal; J Tonascia
Journal:  Aliment Pharmacol Ther       Date:  2013-05-29       Impact factor: 8.171

9.  Non-alcoholic Fatty Liver Disease: East Versus West.

Authors:  Swastik Agrawal; Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

10.  Nonalcoholic fatty liver disease is underrecognized in the primary care setting.

Authors:  Pierre Blais; Nisreen Husain; Jennifer R Kramer; Marc Kowalkowski; Hashem El-Serag; Fasiha Kanwal
Journal:  Am J Gastroenterol       Date:  2014-06-03       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.